knowledge -WSS

knowledge

author：entertainment 2025-09-28 12:08:48 - browse：7

U.S. legislation that would sever ties with Chinese drugmakers would jeopardize the drug supply for millions of American patients if it’s passed, the biotechnology industry’s main trade group has told Congress.

Congress is considering legislation, called the BIOSECURE Act, that would make it difficult for Chinese contract development and manufacturing organizations to do business with biotechnology companies that work with the U.S. federal government. Biotechs hire Chinese CDMOs, as they’re often called, for services that include product manufacturing, development, formulation, packaging, and distribution.

The BIOSECURE Act would stop the federal government from contracting with, or providing grants to, companies that do business with so-called Chinese “companies of concern.” The impact of the legislation would depend in large part on who is in the White House. The White House’s Office of Management and Budget would determine which companies are blacklisted, but a handful of specific companies would automatically go on that list, including the biotech giant WuXi AppTec.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： HIV drugs protect against transmission, even in unprotected sex

leisure time

WSS

How to increase colonoscopy rates? Looks like an AI can help

Update the Apgar Score to remove skin color

Medicare bonuses could stop drug shortages under Senate plan

Shifting the focus from loneliness to social health

NIH documents show early flaws of $1.6 billion long Covid program

ASCO: AstraZeneca says CAR

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

hotspot

At least 13 dead in Texas as scorching temps continue

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

FDA approval of Sarepta Duchenne genetic therapy gives me hope

High breast density mammograms need follow

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Bright Health sells Medicare Advantage business to Molina

Inaction leaves children at risk from dangerous chemotherapy drug

Medical leaders decry Supreme Court decision on affirmative action

CVS is on a mission to consolidate health care. Will it work?

focus

Mass General, Mayo Clinic look to monetize custom

At ASCO, AstraZeneca reports strong data for breast cancer drug

The inclusion problem at the heart of rehabilitation research

NIH documents show early flaws of $1.6 billion long Covid program

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

leisure time

focus

hotspot

knowledge